시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
분자진단 시장 : 분석과 예측(-2034년)
Molecular Diagnostics Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Component, Process, Installation Type, Solutions
상품코드 : 1762168
리서치사 : Global Insight Services LLC
발행일 : 2025년 07월
페이지 정보 : 영문 336 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,582,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 7,968,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,354,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

분자진단 시장은 2024년 177억 달러로 평가되었고, 2034년까지는 639억 달러에 이르고, 약 13.8%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측되고 있습니다. 이 시장에는 중합효소연쇄반응(PCR), 차세대 시퀀싱(NGS), 마이크로어레이 기술이 포함됩니다. 이 시장을 견인하고 있는 것은 감염증의 유행, 유전체학의 진보, 조기 진단 수요입니다.

업계 개요

분자진단 시장은 세계 관세와 지정학적 리스크의 복잡한 그물을 빠져나가 일본, 한국, 중국, 대만공급망에 큰 영향을 주고 있습니다. 일본과 한국은 관세로 인한 취약성을 경감 하기 위해 국내 능력을 강화하고 있으며, 중국은 수출 규제 속에서 국산 기술에 대한 주력을 가속화하고 있습니다. 반도체 공급에서 대만의 중요한 역할은 특히 미중 긴장을 고려할 때 지정학적 민감성에 의해 강조됩니다. 세계의 분자진단 분야는 기술의 진보와 헬스케어 수요 증가에 의해 강력한 성장을 이루어 왔습니다. 이에 따라 시장은 더욱 확대될 전망입니다. 한편, 중동의 분쟁은 에너지 가격에 대한 압력을 계속 주고 있으며, 분자진단의 제조 비용과 공급망의 안정성에 간접적인 영향을 주고 있습니다.

시장 세분화
유형 중합효소 연쇄반응(PCR), 등온 핵산 증폭 기술(INAAT), DNA 시퀀싱, 마이크로어레이, 하이브리드화
제품 시약, 키트, 장비, 소프트웨어
서비스 교육, 교육, 컨설팅, 유지 보수 지원
기술 차세대 시퀀싱(NGS), Sanger Sequence, CRISPR
용도 감염, 종양학, 유전자 검사, 출생 전 검사, 혈액 검사, 미생물학
최종 사용자 병원, 진단 실험실, 학술·연구 기관, 제약 및 바이오테크놀러지 기업
구성요소 소프트웨어, 하드웨어
프로세스 샘플 준비, 증폭, 검출
설치 유형 벤치탑, 휴대용
솔루션 포인트 오브 케어 검사, 집중 실험실 검사

시장 개요

분자진단 시장은 전염병의 유행과 맞춤형 의료에 대한 수요가 높아지면서 견고한 확대를 이어가고 있습니다. 전염병 검사 부문이 지배적인데, 이는 특히 COVID-19 팬데믹과 같은 글로벌 보건 위기 이후 신속하고 정확한 진단 솔루션에 대한 필요성이 높아졌기 때문입니다. 이 부문의 이점은 뛰어난 감도와 특이성을 제공하는 PCR과 차세대 시퀀싱 기술의 발전으로 더욱 강화되었습니다. 종양학 진단은 암 발생률이 증가하고 분자 진단이 치료 계획을 조정하는 데 중추적인 역할을 하는 정밀 종양학으로의 전환에 힘입어 새롭게 부상하는 하위 부문입니다. 유전자 검사도 가계 및 건강 위험 평가에 대한 소비자들의 관심이 높아지면서 탄력을 받고 있습니다. 이 새로운 하위 부문이 가져 오는 잠재적 영향은 크고 조기 발견 향상, 환자 결과 개선, 표적 치료 개발을 촉진하고 건강 진단의 전망을 재구성할 것으로 기대됩니다.

경쟁 개요

시장 세분화 : 분자진단 시장은 다양한 부문으로 구성되어 있으며 감염성 검사가 견인 역할을합니다. 북미는 첨단 의료 인프라와 활발한 연구 활동으로 인해 시장 도입의 최전선에 있으며 아시아태평양은 건강 관리 시스템의 개선과 인지도 향상으로 성장이 가속화되고 있습니다. Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific 등의 주요 기업은 경쟁력을 유지하기 위해 끊임없이 기술 혁신을 하고 있습니다. 향후 분자 진단 시장은 차세대 시퀀싱 및 현장 진단 테스트와 같은 기술 발전에 힘입어 상당한 성장세를 보일 것으로 예상됩니다. 진단에 있어서의 인공지능과 머신러닝의 통합은 정확도와 효율의 향상을 약속합니다.

주요 동향과 촉진요인

분자진단 시장은 기술의 진보와 감염증의 유행 증가에 견인되어 강력한 성장을 이루고 있습니다. 그리고 적시에 임상적 의사 결정을 촉진합니다. 또한, 개별 유전자 프로파일을 기반으로 치료를 조정하는 맞춤형 의료에 대한 수요 증가도 시장을 뒷받침하고 있습니다. 자녀 진단의 응용 확대도 주요 촉진요인입니다. 이 애플리케이션은 질병의 조기 발견과 모니터링에 매우 중요하므로 환자의 결과가 개선됩니다. 합리적인 가격으로 확장 가능한 기술에 투자하는 기업은 시장 점유율을 얻는 데 유리한 입장에 있습니다.

억제요인과 도전 :

분자진단시장은 몇몇 임박한 시장억제요인과 과제에 직면하고 있습니다. 또한 엄격한 승인 프로세스로 인한 규제의 벽에 직면하여 새로운 기술의 도입이 늦어지고 있습니다. 고급 진단 장비를 운영할 수 있는 숙련된 전문가의 가용성이 제한적이라는 점입니다. 이 부족은 분자 진단의 효과적인 활용을 저해합니다. 데이터의 프라이버시 문제가 큰 과제가 되고 있습니다.

목차

제1장 분자진단 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 분자진단 시장 전망

제5장 분자진단 시장 전략

제6장 분자진단 시장 규모

제7장 분자진단 시장 : 유형별

제8장 분자진단 시장 : 제품별

제9장 분자진단 시장 : 서비스별

제10장 분자진단 시장 : 기술별

제11장 분자진단 시장 : 용도별

제12장 분자진단 시장 : 최종 사용자별

제13장 분자진단 시장 : 컴포넌트별

제14장 분자진단 시장 : 프로세스별

제15장 분자진단 시장 : 설치 유형별

제16장 분자진단 시장 : 솔루션별

제17장 분자진단 시장 : 지역별

제18장 경쟁 구도

제19장 기업 프로파일

SHW
영문 목차

영문목차

Molecular Diagnostics Market is anticipated to expand from $17.7 billion in 2024 to $63.9 billion by 2034, growing at a CAGR of approximately 13.8%. Molecular Diagnostics Market encompasses technologies for detecting genetic material in biological samples, aiding in disease diagnosis, management, and personalized medicine. This market includes polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray technologies. It is driven by rising prevalence of infectious diseases, advancements in genomics, and demand for early diagnosis. The market is witnessing innovations in point-of-care testing and companion diagnostics, emphasizing precision and rapid results.

Industry Overview:

The Molecular Diagnostics Market is navigating the intricate web of global tariffs and geopolitical risks, significantly impacting supply chains across Japan, South Korea, China, and Taiwan. Japan and South Korea are bolstering domestic capabilities to mitigate tariff-induced vulnerabilities, while China accelerates its focus on indigenous technology amidst export restrictions. Taiwan's critical role in semiconductor supply is underscored by geopolitical sensitivities, particularly in light of US-China tensions. The global molecular diagnostics sector is witnessing robust growth driven by technological advancements and increased healthcare demands. By 2035, the market is poised for further expansion, contingent on resilient supply chains and strategic regional collaborations. Meanwhile, Middle East conflicts continue to exert pressure on energy prices, indirectly influencing manufacturing costs and supply chain stability in the molecular diagnostics landscape.

Market Segmentation
TypePolymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing, Microarray, Hybridization
ProductReagents and Kits, Instruments, Software
ServicesTraining and Education, Consulting, Maintenance and Support
TechnologyNext-Generation Sequencing (NGS), Sanger Sequencing, CRISPR
ApplicationInfectious Diseases, Oncology, Genetic Testing, Prenatal Testing, Blood Screening, Microbiology
End UserHospitals, Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies
ComponentSoftware, Hardware
ProcessSample Preparation, Amplification, Detection
Installation TypeBenchtop, Portable
SolutionsPoint-of-Care Testing, Centralized Laboratory Testing

Market Overview:

The Molecular Diagnostics Market is experiencing robust expansion, propelled by the growing prevalence of infectious diseases and the rising demand for personalized medicine. The infectious disease testing segment dominates, largely due to the heightened need for rapid and accurate diagnostic solutions, especially in the wake of global health crises such as the COVID-19 pandemic. This segment's supremacy is further bolstered by advancements in PCR and next-generation sequencing technologies, which offer superior sensitivity and specificity. Oncology diagnostics is an emerging sub-segment, driven by the increasing incidence of cancer and the shift towards precision oncology, where molecular diagnostics play a pivotal role in tailoring treatment plans. Genetic testing is also gaining momentum, supported by the rising consumer interest in ancestry and health risk assessments. The potential impact of these emerging sub-segments is significant, as they promise to enhance early detection, improve patient outcomes, and foster the development of targeted therapies, thereby reshaping the landscape of healthcare diagnostics.

Geographical Overview:

The molecular diagnostics market is witnessing notable growth across various regions, each exhibiting unique characteristics. North America maintains a dominant position, driven by advanced healthcare infrastructure and substantial investments in research and development. The presence of major biotechnology companies and a strong focus on personalized medicine further bolster the market. Europe follows closely, with robust government support for healthcare innovations and an increasing demand for early disease detection. The region's strong regulatory framework and emphasis on quality healthcare services enhance its market appeal. In the Asia Pacific, the market is expanding rapidly, propelled by technological advancements and a growing emphasis on healthcare improvements. Rising awareness of early diagnosis and increasing healthcare expenditure contribute to this growth. The region's large population base and increasing prevalence of chronic diseases create lucrative opportunities for market players. Latin America and the Middle East & Africa are emerging markets with significant potential. In Latin America, improving healthcare infrastructure and rising investments in diagnostic technologies drive market expansion. Meanwhile, the Middle East & Africa are recognizing the importance of molecular diagnostics in enhancing healthcare outcomes and addressing unmet medical needs.

Competition Overview:

The molecular diagnostics market is characterized by a diverse distribution of segments, with infectious disease testing leading the charge, closely followed by oncology and genetic testing. This segmentation is fueled by the increasing prevalence of infectious diseases and the rising demand for personalized medicine. North America remains at the forefront of market adoption, driven by advanced healthcare infrastructure and robust research activities, while the Asia-Pacific region witnesses accelerated growth due to improving healthcare systems and increasing awareness. Key players such as Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific are continually innovating to maintain their competitive edge. Regulatory frameworks, particularly in regions like North America and Europe, play a pivotal role in shaping market dynamics, ensuring quality and safety standards. Looking ahead, the molecular diagnostics market is poised for significant growth, driven by technological advancements such as next-generation sequencing and point-of-care testing. The integration of artificial intelligence and machine learning in diagnostics promises to enhance accuracy and efficiency. However, challenges such as regulatory hurdles and high costs of advanced diagnostic tools persist. Nonetheless, the ongoing focus on precision medicine and the rising incidence of chronic diseases present substantial opportunities for market expansion.

Recent Developments:

In recent months, the molecular diagnostics market has witnessed noteworthy developments. Roche Diagnostics announced a strategic collaboration with Illumina to enhance next-generation sequencing capabilities, aiming to accelerate the development of comprehensive diagnostic solutions. Thermo Fisher Scientific launched a novel molecular diagnostic test designed to detect multiple respiratory pathogens, addressing the growing demand for multiplex testing solutions. Qiagen, in partnership with BioNTech, expanded its molecular diagnostic portfolio to include innovative assays targeting oncology and infectious diseases, further solidifying its market position. Abbott Laboratories unveiled a groundbreaking molecular diagnostic platform that significantly reduces test processing time, enhancing efficiency in clinical laboratories. Meanwhile, the European Union introduced updated regulatory guidelines for molecular diagnostics, emphasizing the importance of stringent quality standards and encouraging innovation in the sector. These strategic collaborations, product innovations, and regulatory updates underscore the dynamic nature of the molecular diagnostics market, highlighting significant growth opportunities and advancements in diagnostic technologies.

Key Companies:

Qiagen, Bio- Rad Laboratories, Luminex Corporation, Cepheid, Gen Mark Diagnostics, Hologic, Natera, Adaptive Biotechnologies, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Illumina, Abbott Laboratories, Agilent Technologies, Becton Dickinson, bio Merieux, Quidel, Exact Sciences, Myriad Genetics, Perkin Elmer

Key Trends and Drivers:

The molecular diagnostics market is experiencing robust growth, driven by technological advancements and the increasing prevalence of infectious diseases. Key trends include the integration of artificial intelligence and machine learning in diagnostics, which enhances accuracy and efficiency. The rise of point-of-care testing is another significant trend, offering rapid results and facilitating timely clinical decision-making. Furthermore, the market is propelled by the growing demand for personalized medicine, which tailors treatments based on individual genetic profiles. This demand is fostering innovation in molecular diagnostic tools. The expanding applications of molecular diagnostics in oncology, infectious diseases, and genetic testing are also key drivers. These applications are crucial in early disease detection and monitoring, thereby improving patient outcomes. Opportunities are abundant in emerging markets, where healthcare infrastructure is improving and access to advanced diagnostics is expanding. Companies investing in affordable and scalable technologies are well-positioned to capture market share. Additionally, collaborations between research institutions and industry players are accelerating the development of novel diagnostic solutions, further catalyzing market growth.

Restraints and Challenges:

The molecular diagnostics market is confronted with several pressing restraints and challenges. A significant challenge is the high cost of molecular diagnostic tests, which limits accessibility in low-income regions. This financial barrier deters widespread adoption, affecting market growth. Additionally, the market faces regulatory hurdles due to stringent approval processes, which delay the introduction of new technologies. These regulations vary across countries, complicating global market entry and expansion. Another challenge is the limited availability of skilled professionals capable of operating advanced diagnostic equipment. This shortage hampers the effective utilization of molecular diagnostics. Furthermore, the integration of molecular diagnostics into existing healthcare systems poses significant logistical and technical challenges. Healthcare providers often struggle with interoperability issues, affecting efficiency. Finally, data privacy concerns present a substantial challenge. As molecular diagnostics increasingly rely on genetic data, ensuring patient confidentiality and data security becomes paramount. These challenges collectively impede the rapid advancement of the molecular diagnostics market.

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Molecular Diagnostics Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Molecular Diagnostics Market Outlook

5: Molecular Diagnostics Market Strategy

6: Molecular Diagnostics Market Size

7: Molecular Diagnostics Market, by Type

8: Molecular Diagnostics Market, by Product

9: Molecular Diagnostics Market, by Services

10: Molecular Diagnostics Market, by Technology

11: Molecular Diagnostics Market, by Application

12: Molecular Diagnostics Market, by End User

13: Molecular Diagnostics Market, by Component

14: Molecular Diagnostics Market, by Process

15: Molecular Diagnostics Market, by Installation Type

16: Molecular Diagnostics Market, by Solutions

17: Molecular Diagnostics Market, by Region

18: Competitive Landscape

19: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기